Imiquimod: 5 agencies, 2004–2019
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
The file has been open for more than a decade: 15.2 years separate the first record, 10 Aug 2004 at AWMSG (Wales), from the most recent, 11 Nov 2019 at SMC (Scotland).
No assessment is on file from PBAC (Australia), CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
Not every gap is a refusal: for imiquimod, 1 submission was never made — an outcome set by the company rather than the assessor.
Nothing has been added since 2019; on this evidence the file is dormant.
4 distinct indication wordings are recorded for imiquimod by the agencies that label one in English (AWMSG and SMC).
AWMSG (Wales) was first to assess imiquimod, on 10 Aug 2004; SMC (Scotland) did not open a file until 9 Dec 2013 — an unusually long tail of 9.3 years between the earliest and latest system to look at it.
The record arrives in waves: 4 separate years each carry two or more decisions, spread across 9 years in total.
4 of the 5 agencies here assessed imiquimod more than once, PHARMAC (New Zealand) most often at 5 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 5 of the 18 agencies here have assessed imiquimod.
The full ledger for imiquimod reads 7 recommended, 4 not assessed, 2 not recommended and 1 restricted, with 2 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| SMC (Scotland) | 11 Nov 2019 | Topical treatment of clinically typical, nonhyperkeratotic, nonhypertrophic, visible or palpable actinic keratosis (AK) of the full face or balding scalp in immunocompete… | accepted (restricted) | source |
| HAS (France) | 19 Oct 2016 | Change to listing conditions (Transparency Committee) | SMR substantial | source |
| TLV (Sweden) | 13 Sep 2013 | Zyclara ingår i högkostnadsskyddet | general subsidy | source |
| AWMSG (Wales) | 5 Mar 2013 | Topical treatment of clinically typical, nonhyperkeratotic, nonhypertrophic, visible or palpable actinic keratosis of th… | outside AWMSG criteria | source |
| PHARMAC (New Zealand) | 25 Feb 2010 | Actinic keratosis | PTAC advice: Decline · decision reached | source |
11 further decisions for imiquimod, across 4 agencies, are not shown here. They link to 9 further source documents.
Related molecules
- aciclovir — same ATC class D06B — Dermatological anti-infectives
- glibenclamide — also decided by SMC in 2019Q4
- axicabtagene ciloleucel — also decided by SMC in 2019Q4
- ibrutinib — also decided by SMC in 2019Q4
- lusutrombopag — also decided by SMC in 2019Q4
- risankizumab — also decided by SMC in 2019Q4
Coverage: 16 decisions for imiquimod from 5 agencies, 2004 to 2019. Data to 7 Sep 2026. ATC class D06B — Dermatological anti-infectives. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.